Epidermicin NI01 effective for drug-resistant skin infections
19 June 2026We are pleased to share the publication of a new peer-reviewed study in the Journal of Antimicrobial Chemotherapy – Antimicrobial…
We are pleased to share the publication of a new peer-reviewed study in the Journal of Antimicrobial Chemotherapy – Antimicrobial…
From 17th-22nd April, Mat and Vicky headed to Munich, Germany for ESCMID GLOBAL 2026
Last week, CSO Mat Upton and CEO Gordon Barker travelled to Basel, Switzerland for the BEAM Alliance 10th AMR meeting.…
On 14th December, CSO Mat Upton was invited to attend the Final Forum of the Saudi Biotechnology Accelerator (SBA) in…
Amprologix celebrates research excellence at the University of Plymouth as CSO Professor Mat Upton presents the Research Excellence Award to…
On 14th December, CSO Mat Upton was invited to attend the Final Forum of the Saudi Biotechnology Accelerator (SBA) in Riyadh, Saudi Arabia. The event marked the culmination of the 2025 Accelerator Programme and brought together innovators, investors, mentors, and ecosystem leaders from across the global biotechnology sector.
Amprologix has raised £740,000 to accelerate the development of our breakthrough antibiotic Epidermicin NI01. This investment also supports our AI-driven antimicrobial discovery platform, reinforcing our mission to tackle global antimicrobial resistance by developing novel antimicrobials.
Innovate UK has awarded Amprologix £1M of Biomedical Catalyst funding to continue the Tobraderm project 1st March 2024 Amprologix is delighted to receive confirmation of its success in securing a £1M Biomedical Catalyst award from Innovate UK for its Tobraderm project. The project will advance the company’s NI01 lead compound through late-preclinical testing for common […]
